BG Medical Technologies Upgraded to “Current” Status by OTC Markets
July 07 2014 - 8:37AM
Business Wire
BG Medical Technologies, Inc. (OTC: RIGH) has by now been
upgraded by OTC Markets to OTC Markets Current reporting status.
OTC Markets is now providing quotes by listing full information for
the company.
“Our focus is on the long-term growth of our business. By
popular demand of our shareholders, who are partners and co-owners
of the company, we will continue to enhance public communication by
now increasing transparency. We are committed to voluntarily
submitting these reports on an ongoing basis,” stated CEO Angel
Stanz.
Shareholders have now expressed that by these efforts the
company could grow shareholder value and increase the company’s
base of prospective business contacts.
“We are not here to generate a quick buck, but rather to
introduce a get rich slowly plan. Our business model presents a
great way to grow with medical cannabis opportunities on a strong
and steady path. Our true partners are our buy-and-hold investors.
While our upgraded reporting status may be beneficial for day
traders, we want to be clear that we are holding to our long term
commitments by serving the needs of our true shareholders through
building business and by growing the company.”
BG Medical Technologies and BudGenius.com are established
medical marijuana brands, serving the industry since 2010 by
cannabis laboratory analysis and by Internet technology related
services.
About BG Medical Technologies
BG Medical Technologies is a medical marijuana company that
develops technology and research software for cannabis and natural
health solutions. The Company collects data through a network of
proprietary software, utilized by patients, by retail operators,
and by medical professionals. The Company's current flagship
product, BudGenius.com, is a social web platform connecting
cannabis patients to regionally available medicine that is paired
to their needs. The Company operates an analytical chemistry
laboratory designed for cannabis study, utilized to determine
potency and safety guidance for patients and medicine
manufacturers.
For more information please
visit:http://www.BudGenius.comhttp://www.BgMedTech.com
The foregoing press announcement contains forward-looking
statements that can be identified by such terminology such as
"believes," "expects," "potential," "plans," "suggests," "may,"
"should," "could," "intends," or similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results
to be materially different from any future results, performance or
achievements expressed or implied by such statements. In
particular, management's expectations could be affected by, among
other things, uncertainties relating to our success in completing
acquisitions, financing our operations, entering into strategic
partnerships, engaging management and other matters disclosed by us
in our public filings from time to time. Forward-looking statements
speak only as to the date they are made. The Company does not
undertake to update forward-looking statements to reflect
circumstances or events that occur after the date the
forward-looking statements are made.
BG Medical Technologies, Inc.Angel StanzChief Executive
Officer855-723-3283pr@budgenius.com
RightSmile (CE) (USOTC:RIGH)
Historical Stock Chart
From Mar 2024 to Apr 2024
RightSmile (CE) (USOTC:RIGH)
Historical Stock Chart
From Apr 2023 to Apr 2024